Salvarx Share Discussion Threads

[the stigologist] 22/6/2017 11:32

Mr Mellon sounding very confident about Salva rx

[the stigologist] 22/6/2017 09:23

Also I think FFWD had RNS on Intensity couple of days ago but SALV didn't

[wiseacre] 22/6/2017 09:20

i believe the guinea pig(I mean one patient) that is receiving the Intensity Therapeutics treatment is not only still alive but the tumour has markedly reduced.
Hold the front page!

[korvet] 21/6/2017 15:24

Funny said that on lse

[joemillion] 21/6/2017 14:46

Boooooooommm!!!!

[spectoacc] 21/6/2017 13:38

Wow. Does nothing for ever, now this in days, all on "no news".

[the stigologist] 21/6/2017 12:22

Close to a breakout. Wonder if there is any news imminent?

[kingston78] 20/6/2017 15:56

Something is up. It is unusual for the share price to move this much. I suspect that some people know something that I don't. should be positive.

[spectoacc] 20/6/2017 07:15

Seen no news but seeing some keen buyers & small free float makes it very interesting.

[joemillion] 19/6/2017 21:36

Certainly does. Up over 9% today on five small buys. Only a matter of time before it really takes over.

[kingston78] 08/6/2017 13:05

Does anyone have any news about this company? The share price sometimes move by quite a bit without any apparent reason?

[doodlebug4] 30/5/2017 13:42

Some more details about the trials from www.clinicaltrials.gov

[spectoacc] 30/5/2017 12:26

Finally some news - hopefully soon going to get very interesting!

[fig1] 06/4/2017 13:53

Great news today.Anyone selling HAS to sell for whatever reason.Fig.

[the stigologist] 06/4/2017 11:03

WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that tumor regression and immune activation data generated by the Company’s lead drug, INT230-6, will be presented in a poster session at the American Academy of Cancer Research (AACR) meeting on April 5, 2017. The research being presented indicates that INT230-6 results in complete response of tumors in rodent models, induces protective T cell immunity and is synergistic with checkpoint inhibitors. Dr. Anja Bloom from the Vaccine Branch of the National Cancer Institute (NCI) and Lewis H. Bender, CEO of Intensity Therapeutics will present the poster presentation.

[kingston78] 06/4/2017 10:37

We should back this company. The amount of investment depends on your risk appetite. We may hit the jackpot one day.

[the stigologist] 27/3/2017 21:16

www.proactiveinvestors.co.uk/columns/northland-capital-partners-view-on-the-city/27337/northland-capital-partners-view-on-the-city-immupharma-plc-salvarx

SalvaRx (LON:SALV) – BUY*: New investment

Market Cap: £11m; Current Price: 29p; Target Price: 149p

Investment in Rift Biotherapeutics Inc.

SalvaRx announced that it has entered into an agreement to invest in Rift Biotherapeutics Inc. (Rift), a private, Delaware-domiciled biotechnology company focused on the development of antibodies for use in oncology.

Under the terms of the agreement, SalvaRx will invest US$1,000,000 for an initial holding of approximately 30% (including new shares issued on the conversion of a US$90,000 convertible loan already provided to Rift) in the company.

Subject to Rift achieving certain development milestones with this initial funding, SalvaRx has the option to invest up to an additional US$1,500,000 at the same valuation and to acquire all outstanding shares of Rift in exchange for new shares in SalvaRx on the same basis.

The initial investment has been funded from existing cash resources.

Rift, an early stage research and development company, was founded in 2015 in order to discover and develop first-in-class antibodies implicated in the inflammatory tumour and tumour infiltrating immune cells microenvironment.

NORTHLAND CAPITAL PARTNERS VIEW: SalvaRx continues delivering on its expansion strategy of building a broad portfolio of immune-oncology assets. Rift represents SalvaRx’s fourth immune-oncology portfolio company. The group has discovered several candidate antibodies to novel immune check point targets. The group’s novel non T-cell based immunotherapy targets offer complementary approaches to the current standard of care in this area. The market for immuno-oncology products is forecast to expand to $80bn by 2020.

[spectoacc] 27/3/2017 08:27

Agreed, with the added kicker of a restricted free float - if there is reason for it to fly, it should really go for it.

[kingston78] 27/3/2017 08:21

Patience is the virtue in this sort of investment. One may hit the jackpot one day.

Good luck.

[spectoacc] 27/3/2017 07:03

Thanks, seems to have caused a few buys first thing in a negative market.

[fig1] 25/3/2017 21:56

SalvaRx one of Jim Mellon's featured 'longs' at Master Investor conference this weekend.Hang in there.Fig.

[spectoacc] 14/3/2017 15:39

All gone quiet - still waiting for news on first patient dosing, and will then have to wait for news on how that's gone.

[fig1] 03/3/2017 21:35

Yes,big swings possible short term but I'm hoping for that money fountain JM speaks about.

[the stigologist] 03/3/2017 15:21

Mellon needs to start delivering here. Whineyfroth having a good laugh at all the perceived 'failures' from his 'old friend'.